Olmesartan Medoxomil Crescent Pharma

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomil Crescent Pharma, is an Angiotensin II receptor blocker (ARB) presented as a tablet for oral use. It is indicated for the management of hypertension in adult patients. GNH USA supplies Olmesartan Medoxomil Crescent Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olmesartan Medoxomil Crescent Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan Medoxil is an ARB that lowers blood pressure by blocking the renin‑angiotensin system.

- Hypertension: helps achieve target blood pressure and reduces cardiovascular risk. - Diabetic nephropathy: slows progression of kidney damage associated with diabetes. - Heart failure: used as part of combination therapy to improve outcomes in patients with reduced ejection fraction.

Olmesartan Medoxil is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Dizziness - Headache - Fatigue - Nasal congestion - Diarrhea

Serious or Rare Side Effects: - Angio‑edema - Hyperkalemia - Acute kidney injury - Severe hypotension - Liver enzyme elevations

When prescribing Olmesartan Medoxil, clinicians should consider several safety aspects.

- Renal function: assess baseline kidney function and monitor periodically. - Electrolytes: check serum potassium, especially if combined with potassium‑sparing diuretics. - Pregnancy: contraindicated in the second and third trimesters due to fetal toxicity. - Elderly patients: start at lower dose and monitor for orthostatic hypotension. - Drug interactions: review concomitant medications that affect the renin‑angiotensin system. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Olmesartan Medoxil may interact with several medicines that influence blood pressure or renal function.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): increased risk of renal impairment, hyperkalemia, and hypotension. - Potassium‑sparing diuretics (e.g., spironolactone): risk of hyperkalemia.

Moderate Interactions (Monitor Closely): - NSAIDs (e.g., ibuprofen): may blunt antihypertensive effect and affect renal function. - ACE inhibitors or other ARBs: additive hypotensive effect, monitor blood pressure. - Lithium: may increase serum lithium levels, monitor for toxicity.